Short Interest in Genfit S.A. (NASDAQ:GNFT) Declines By 40.5%

Genfit S.A. (NASDAQ:GNFT) was the recipient of a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 60,300 shares, a decrease of 40.5% from the January 31st total of 101,300 shares. Based on an average daily trading volume, of 8,400 shares, the short-interest ratio is presently 7.2 days. Currently, 0.1% of the shares of the company are short sold.

Hedge Funds Weigh In On Genfit

An institutional investor recently bought a new position in Genfit stock. Millennium Management LLC bought a new position in shares of Genfit S.A. (NASDAQ:GNFT) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 166,375 shares of the company’s stock, valued at approximately $611,000. Millennium Management LLC owned 0.33% of Genfit at the end of the most recent quarter. 2.24% of the stock is currently owned by institutional investors.

Genfit Stock Up 2.1 %

Shares of NASDAQ GNFT traded up $0.07 during trading hours on Tuesday, reaching $3.47. 16,612 shares of the stock were exchanged, compared to its average volume of 8,895. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74. Genfit has a 52 week low of $3.35 and a 52 week high of $6.42. The stock’s fifty day simple moving average is $3.73 and its 200 day simple moving average is $4.40.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Genfit in a research note on Friday, February 7th.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.